This HTML5 document contains 77 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://www.rxlist.com/cgi/generic3/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00307/identifier/pubchem-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00307/identifier/pubchem-substance/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00307/identifier/drugbank/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00307/identifier/iuphar/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00307/identifier/guide-to-pharmacology/
n27http://bio2rdf.org/drugbank:
n25http://linked.opendata.cz/resource/drugbank/drug/DB00307/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n26http://linked.opendata.cz/resource/drugbank/patent/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00307/identifier/chemspider/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00307/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n5http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00307/identifier/wikipedia/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00307/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00307
rdf:type
n3:Drug
n3:description
Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. [Wikipedia]
n3:dosage
n14:271B4F3F-363D-11E5-9242-09173F13E4C5 n14:271B4F40-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, Ranki A, Schwandt P, Whittaker S: The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol. 2007 Sep;157(3):433-40. Epub 2007 Jun 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17553039 # Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, Nugent WC, Hermann T, Negro-Vilar A, Rigas JR, Dmitrovsky E: A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res. 2007 Mar 15;13(6):1794-800. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17363535 # Smit JW, Stokkel MP, Pereira AM, Romijn JA, Visser TJ: Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. J Clin Endocrinol Metab. 2007 Jul;92(7):2496-9. Epub 2007 Apr 17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17440015 # Lowe MN, Plosker GL: Bexarotene. Am J Clin Dermatol. 2000 Jul-Aug;1(4):245-50; discussion 251-2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11702369 # Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW: A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer. 2006 Mar 13;94(5):654-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16495926 # Farol LT, Hymes KB: Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004 Apr;4(2):180-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15056048
n3:group
approved investigational
n3:halfLife
7 hours
n3:indication
Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.
n3:manufacturer
n11:271B4F3B-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00307 n27:DB00307
dcterms:title
Bexarotene
adms:identifier
n8:50859 n17:2807 n18:Bexarotene n19:2807 n20:74139 n21:DB00307 n22:82146 n23:PA164752250 n24:46509119 n25:64365-502-01
n3:mechanismOfAction
Bexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXR<sub>α</sub>, RXR<sub>β</sub>, RXR<sub>γ</sub>. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL.
n3:packager
n11:271B4F38-363D-11E5-9242-09173F13E4C5 n11:271B4F39-363D-11E5-9242-09173F13E4C5 n11:271B4F3A-363D-11E5-9242-09173F13E4C5
n3:patent
n26:5962731 n26:6043279
n3:routeOfElimination
Urinary elimination of bexarotene and its known metabolites is a minor excretory pathway (<1% of administered dose).
n3:synonym
Bexaroten Bexaroteno Bexarotene Targrexin 4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid Targretyn Bexarotenum 4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid Bexarotène p-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl]benzoic acid
n3:proteinBinding
>99%
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Bexarotene.htm
foaf:page
n5:bexarotene.html n13:bexarotene.htm
n3:IUPAC-Name
n6:271B4F45-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B4F4B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B4F4A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B4F47-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B4F48-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B4F49-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B4F43-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B4F5A-363D-11E5-9242-09173F13E4C5 n6:271B4F44-363D-11E5-9242-09173F13E4C5 n6:271B4F41-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B4F42-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:L01XX25
n3:H-Bond-Acceptor-Count
n6:271B4F51-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B4F52-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B4F4C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B4F4D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B4F4F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B4F4E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B4F50-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
153559-49-0
n3:containedIn
n28:271B4F3D-363D-11E5-9242-09173F13E4C5 n28:271B4F3E-363D-11E5-9242-09173F13E4C5 n28:271B4F3C-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B4F56-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B4F58-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B4F59-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B4F55-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B4F54-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B4F57-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B4F46-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B4F53-363D-11E5-9242-09173F13E4C5